Related Experiment Videos

Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis

Jack L Leahy1

  • 1Colchester Research Facility, Colchester, VT 05446, USA. jleahy@uvm.edu

Current Diabetes Reports
|June 4, 2009
PubMed

Insights

Thiazolidinediones (TZDs) show high success in prediabetes and early type 2 diabetes. Emerging research highlights peroxisome proliferator-activated receptor (PPAR)gamma signaling in beta cells as a key mechanism.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Thiazolidinediones (TZDs) are established treatments for prediabetes and type 2 diabetes.
  • Their mechanism was thought to be solely improving insulin sensitivity.
  • A newer hypothesis focuses on preserving beta-cell function.

Purpose of the Study:

  • To review TZD intervention studies in prediabetes and type 2 diabetes.
  • To explore the beta-cell overwork and rest hypotheses.
  • To present recent findings on peroxisome proliferator-activated receptor (PPAR)gamma signaling in beta cells.

Main Methods:

  • Review of clinical trial data on TZD efficacy.
  • Analysis of current concepts in beta-cell physiology.
  • Synthesis of recent research on PPARgamma signaling pathways.

Main Results:

  • TZDs demonstrate significant clinical success in managing prediabetes and early type 2 diabetes.
  • The understanding of TZD mechanisms has evolved from insulin sensitization to beta-cell preservation.
  • Peroxisome proliferator-activated receptor (PPAR)gamma signaling exerts potent biological effects within islet beta cells.

Conclusions:

  • TZDs may preserve beta-cell function, potentially through mechanisms involving PPARgamma signaling.
  • Understanding these pathways offers new insights into diabetes treatment.
  • Further research into PPARgamma's role could refine therapeutic strategies for diabetes.

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...